

Title (en)
MODIFIED CELL EXPANSION AND USES THEREOF

Title (de)
MODIFIZIERTE ZELLEXPANSION UND VERWENDUNGEN DAVON

Title (fr)
EXPANSION DE CELLULES MODIFIÉES ET SES UTILISATIONS

Publication
EP 3908294 A4 20221228 (EN)

Application
EP 20739064 A 20200110

Priority

- US 201962790783 P 20190110
- US 201962799462 P 20190131
- US 201962816497 P 20190311
- US 201962817322 P 20190312
- US 201916387166 A 20190417
- US 201962846563 P 20190510
- US 201962848961 P 20190516
- US 201916445965 A 20190619
- US 201962889926 P 20190821
- US 201962891131 P 20190823
- US 201962902766 P 20190919
- US 201962932587 P 20191108
- US 2020013099 W 20200110

Abstract (en)
[origin: WO2020146743A1] The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering a mixed population of T cells comprising modified T cells comprising a first chimeric antigen receptor (CAR) and modified T cells comprising a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.

IPC 8 full level
A61K 39/00 (2006.01); **A61K 38/20** (2006.01); **A61K 38/21** (2006.01); **A61P 35/00** (2006.01); **C07K 14/725** (2006.01); **C07K 16/28** (2006.01); **C12N 5/0783** (2010.01)

CPC (source: CN EP KR US)
A61K 35/17 (2013.01 - KR); **A61K 38/204** (2013.01 - KR); **A61K 38/217** (2013.01 - KR); **A61K 39/0011** (2013.01 - KR); **A61K 39/001112** (2018.08 - CN); **A61K 39/001113** (2018.08 - CN); **A61K 39/001117** (2018.08 - CN); **A61K 39/00114** (2018.08 - CN); **A61K 39/001141** (2018.08 - CN); **A61K 39/4611** (2023.05 - EP US); **A61K 39/4631** (2023.05 - EP US); **A61K 39/464412** (2023.05 - EP US); **A61K 39/464444** (2023.05 - EP US); **A61K 39/46447** (2023.05 - EP US); **A61K 39/464481** (2023.05 - EP US); **A61K 39/464488** (2023.05 - EP US); **A61K 2239/30** (2023.05 - US); **A61K 2239/50** (2023.05 - US); **A61P 35/00** (2018.01 - CN EP KR); **C07K 14/4748** (2013.01 - EP); **C07K 14/5412** (2013.01 - CN US); **C07K 14/5434** (2013.01 - CN); **C07K 14/57** (2013.01 - CN US); **C07K 14/7051** (2013.01 - CN EP US); **C07K 14/70521** (2013.01 - US); **C07K 14/70578** (2013.01 - US); **C07K 16/28** (2013.01 - KR); **C07K 16/2803** (2013.01 - CN EP US); **C07K 16/2869** (2013.01 - EP); **C07K 16/2878** (2013.01 - CN); **C07K 16/30** (2013.01 - CN KR); **C12N 5/0635** (2013.01 - EP US); **C12N 5/0636** (2013.01 - CN EP US); **A61K 2039/505** (2013.01 - US); **A61K 2039/5156** (2013.01 - KR); **A61K 2039/5158** (2013.01 - CN KR); **A61K 2039/585** (2013.01 - KR); **A61K 2039/804** (2018.08 - KR); **A61K 2039/812** (2018.08 - EP); **A61K 2039/82** (2018.08 - EP); **A61K 2039/836** (2018.08 - EP); **A61K 2039/852** (2018.08 - EP); **A61K 2239/30** (2023.05 - EP); **A61K 2239/50** (2023.05 - EP); **A61K 2300/00** (2013.01 - KR); **C07K 2317/24** (2013.01 - EP); **C07K 2317/31** (2013.01 - EP); **C07K 2317/622** (2013.01 - EP US); **C07K 2317/73** (2013.01 - EP); **C07K 2319/02** (2013.01 - US); **C07K 2319/03** (2013.01 - EP US); **C07K 2319/30** (2013.01 - US); **C07K 2319/33** (2013.01 - CN EP US); **C12N 2501/515** (2013.01 - EP); **C12N 2501/599** (2013.01 - EP); **C12N 2510/00** (2013.01 - CN EP); **C12N 2740/15041** (2013.01 - KR); **C12N 2740/16043** (2013.01 - EP)

Citation (search report)

- [XYI] WO 2017149515 A1 20170908 - NOVARTIS AG [CH], et al
- [X] WO 2016164731 A2 20161013 - NOVARTIS AG [CH], et al
- [Y] WO 2017120525 A1 20170713 - UNIV NORTH CAROLINA CHARLOTTE [US]
- [E] WO 2020086989 A1 20200430 - INNOVATIVE CELLULAR THERAPEUTICS CO LTD [CN], et al
- [XPI] WO 2019140100 A1 20190718 - INNOVATIVE CELLULAR THERAPEUTICS INC [US], et al
- [Y] NAN CHEN ET AL: "CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy", ONCOIMMUNOLGY, 23 December 2016 (2016-12-23), US, pages 1 - 3, XP055345977, ISSN: 2162-4011, DOI: 10.1080/2162402X.2016.1273302
- [Y] MYTHILI KONERUA ET AL: "IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo", ONCOIMMUNOLOGY, vol. 4, no. 3, 23 January 2015 (2015-01-23), pages 1 - 11, XP009184024, ISSN: 2162-402X, [retrieved on 20150123], DOI: 10.4161/2162402X.2014.994446
- [T] LEÓN-TRIANA ODELAISY ET AL: "Dual-Target CAR-Ts with On- and Off-Tumour Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept", CANCERS, vol. 13, no. 4, 9 February 2021 (2021-02-09), pages 703, XP055980288, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916125/pdf/cancers-13-00703.pdf> DOI: 10.3390/cancers13040703
- See also references of WO 2020146743A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2020146743 A1 20200716; AU 2020206359 A1 20210729; CN 113677353 A 20211119; CN 117802050 A 20240402; CN 117802051 A 20240402; EP 3908294 A1 20211117; EP 3908294 A4 20221228; KR 20210114969 A 20210924; SG 11202107269X A 20210729; US 2022096546 A1 20220331

DOCDB simple family (application)

US 2020013099 W 20200110; AU 2020206359 A 20200110; CN 202080008597 A 20200110; CN 202410016585 A 20200110;
CN 202410022941 A 20200110; EP 20739064 A 20200110; KR 20217025235 A 20200110; SG 11202107269X A 20200110;
US 202017420066 A 20200110